MUC1 with excessive O-glycosylation also increased the expression of MDR proteins and ultimately attenuated the sensitivity of HER2+ and/or ER+ breast cancer cells to bortezomib, trastuzumab, and tamoxifen [212]. This evidence concerns the gene ESR1 and breast carcinoma.